Nov 29, 2021 8:05am EST Inhibikase Therapeutics Announces Publication Highlighting Mechanism of Disease and the Potential of Oral c-Abl Kinase Inhibitor Therapy for the Treatment of Parkinson's Disease
Nov 15, 2021 5:30pm EST Inhibikase Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
Oct 27, 2021 8:05am EDT Inhibikase Therapeutics to Participate in Upcoming Michael J. Fox Foundation Alpha-Synuclein Summit
Oct 19, 2021 8:05am EDT Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009
Oct 04, 2021 8:05am EDT Inhibikase Therapeutics Announces Interim Three-month Results from Chronic Toxicology Studies of its Oral c-Abl Kinase Inhibitor, IkT-148009, in Development for Treatment of Parkinson's Disease
Sep 23, 2021 8:05am EDT Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy
Sep 07, 2021 8:00am EDT Inhibikase Therapeutics to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment Conference
Aug 16, 2021 4:45pm EDT Inhibikase Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity
Jul 26, 2021 8:42am EDT Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients